AR126154A1 - Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 - Google Patents
Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3Info
- Publication number
- AR126154A1 AR126154A1 ARP220101578A ARP220101578A AR126154A1 AR 126154 A1 AR126154 A1 AR 126154A1 AR P220101578 A ARP220101578 A AR P220101578A AR P220101578 A ARP220101578 A AR P220101578A AR 126154 A1 AR126154 A1 AR 126154A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide chain
- specificity
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/066141 WO2022262959A1 (en) | 2021-06-15 | 2021-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126154A1 true AR126154A1 (es) | 2023-09-13 |
Family
ID=77519090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101578A AR126154A1 (es) | 2021-06-15 | 2022-06-15 | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11739145B2 (https=) |
| EP (1) | EP4355428A1 (https=) |
| JP (2) | JP7513854B2 (https=) |
| KR (1) | KR20240032847A (https=) |
| CN (1) | CN117858906A (https=) |
| AR (1) | AR126154A1 (https=) |
| AU (1) | AU2022292895A1 (https=) |
| BR (1) | BR112023026566A2 (https=) |
| CA (1) | CA3222300A1 (https=) |
| CL (1) | CL2023003725A1 (https=) |
| CO (1) | CO2023017378A2 (https=) |
| IL (1) | IL308072A (https=) |
| MX (1) | MX2023014666A (https=) |
| TW (1) | TW202317624A (https=) |
| WO (2) | WO2022262959A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| KR20250120305A (ko) * | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2025120867A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| AR134560A1 (es) * | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120866A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| CN110894240B (zh) * | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| JOP20210022A1 (ar) | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| US20230192903A1 (en) * | 2020-05-29 | 2023-06-22 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody against cldn18.2 and cd3 |
-
2021
- 2021-06-15 WO PCT/EP2021/066141 patent/WO2022262959A1/en not_active Ceased
-
2022
- 2022-06-15 AR ARP220101578A patent/AR126154A1/es unknown
- 2022-06-15 BR BR112023026566A patent/BR112023026566A2/pt unknown
- 2022-06-15 KR KR1020247001571A patent/KR20240032847A/ko active Pending
- 2022-06-15 AU AU2022292895A patent/AU2022292895A1/en active Pending
- 2022-06-15 MX MX2023014666A patent/MX2023014666A/es unknown
- 2022-06-15 WO PCT/EP2022/066299 patent/WO2022263508A1/en not_active Ceased
- 2022-06-15 IL IL308072A patent/IL308072A/en unknown
- 2022-06-15 EP EP22750661.5A patent/EP4355428A1/en active Pending
- 2022-06-15 CN CN202280042413.9A patent/CN117858906A/zh active Pending
- 2022-06-15 CA CA3222300A patent/CA3222300A1/en active Pending
- 2022-06-15 TW TW111122151A patent/TW202317624A/zh unknown
- 2022-06-15 JP JP2023577405A patent/JP7513854B2/ja active Active
- 2022-12-06 US US18/062,465 patent/US11739145B2/en active Active
-
2023
- 2023-07-05 US US18/347,361 patent/US12378313B2/en active Active
- 2023-12-13 CL CL2023003725A patent/CL2023003725A1/es unknown
- 2023-12-14 CO CONC2023/0017378A patent/CO2023017378A2/es unknown
-
2024
- 2024-06-10 JP JP2024093451A patent/JP2024116283A/ja active Pending
-
2025
- 2025-07-11 US US19/267,078 patent/US20260035458A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4355428A1 (en) | 2024-04-24 |
| MX2023014666A (es) | 2024-01-12 |
| CL2023003725A1 (es) | 2024-05-17 |
| TW202317624A (zh) | 2023-05-01 |
| CN117858906A (zh) | 2024-04-09 |
| US12378313B2 (en) | 2025-08-05 |
| US20230137677A1 (en) | 2023-05-04 |
| BR112023026566A2 (pt) | 2024-03-05 |
| KR20240032847A (ko) | 2024-03-12 |
| CA3222300A1 (en) | 2022-12-22 |
| WO2022262959A1 (en) | 2022-12-22 |
| AU2022292895A1 (en) | 2024-01-04 |
| US11739145B2 (en) | 2023-08-29 |
| JP7513854B2 (ja) | 2024-07-09 |
| JP2024116283A (ja) | 2024-08-27 |
| CO2023017378A2 (es) | 2024-02-05 |
| WO2022263508A1 (en) | 2022-12-22 |
| IL308072A (en) | 2023-12-01 |
| JP2024520868A (ja) | 2024-05-24 |
| US20260035458A1 (en) | 2026-02-05 |
| US20240018234A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126154A1 (es) | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| AR110979A1 (es) | Moléculas de unión a cd70 y métodos de uso de las mismas | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| MX369276B (es) | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| MX2024009976A (es) | Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. | |
| PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
| AR120741A1 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| AR126464A1 (es) | Agentes para el tratamiento de cánceres positivos para cldn6 | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| AR124289A1 (es) | Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos | |
| PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| ZA202305217B (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| AR087485A1 (es) | Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc | |
| AR130641A1 (es) | Anticuerpos anti-cd28 |